• español
  • English
  • français
  • Deutsch
  • português (Brasil)
  • italiano
    • español
    • English
    • français
    • Deutsch
    • português (Brasil)
    • italiano
    • español
    • English
    • français
    • Deutsch
    • português (Brasil)
    • italiano
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Stöbern

    Gesamter BestandBereicheErscheinungsdatumAutorenSchlagwortenTiteln

    Mein Benutzerkonto

    Einloggen

    Statistik

    Benutzungsstatistik

    Compartir

    Dokumentanzeige 
    •   UVaDOC Startseite
    • WISSENSCHAFTLICHE ARBEITEN
    • Departamentos
    • Dpto. Biología Celular, Genética, Histología y Farmacología
    • DEP05 - Artículos de revista
    • Dokumentanzeige
    •   UVaDOC Startseite
    • WISSENSCHAFTLICHE ARBEITEN
    • Departamentos
    • Dpto. Biología Celular, Genética, Histología y Farmacología
    • DEP05 - Artículos de revista
    • Dokumentanzeige
    • español
    • English
    • français
    • Deutsch
    • português (Brasil)
    • italiano

    Exportar

    RISMendeleyRefworksZotero
    • edm
    • marc
    • xoai
    • qdc
    • ore
    • ese
    • dim
    • uketd_dc
    • oai_dc
    • etdms
    • rdf
    • mods
    • mets
    • didl
    • premis

    Citas

    Por favor, use este identificador para citar o enlazar este ítem:http://uvadoc.uva.es/handle/10324/9060

    Título
    EUDRAGENE: European collaboration to establish a case–control DNA collection for studying the genetic basis of adverse drug reactions
    Autor
    Molokhia, Mariam
    McKeigue, Paul
    Año del Documento
    2006
    Editorial
    Future Medicine
    Descripción
    Producción Científica
    Documento Fuente
    Pharmacogenomics. 2006 Jun;7(4):633-8.
    Zusammenfassung
    Type B adverse drug reactions (ADRs) are often serious, limit the usefulness of drugs that are otherwise effective, and increase the risks of drug development as they often lead to postmarketing withdrawal. There is evidence that susceptibility to at least some Type B ADRs is under strong genetic influence. Identifying genes in which variation influences susceptibility has obvious practical value for genetic testing and might also make it easier to screen molecules likely to cause ADRs at an early stage of the drug development process. Research in this area is hampered by the lack of a resource in which to study genetic determinants of susceptibility to Type B ADRs. As serious Type B ADRs are rare, case-control designs are the most frequently-used approach. The EUDRAGENE collaboration seeks to develop a resource using an international collaboration. This will provide a basis for adverse drug susceptibility genome association-wide studies using tag single nucleotide polymorphisms, or a direct approach using putative functional polymorphisms.
    Materias (normalizadas)
    Medicamentos - Efectos adversos
    ISSN
    1462-2416
    Revisión por pares
    SI
    DOI
    10.2217/14622416.7.4.633
    Idioma
    eng
    URI
    http://uvadoc.uva.es/handle/10324/9060
    Derechos
    openAccess
    Aparece en las colecciones
    • DEP05 - Artículos de revista [198]
    Zur Langanzeige
    Dateien zu dieser Ressource
    Nombre:
    Carvajal 20 PD-215.pdf
    Tamaño:
    288.6Kb
    Formato:
    Adobe PDF
    Descripción:
    PD-215
    Thumbnail
    Öffnen
    Attribution-NonCommercial-NoDerivatives 4.0 InternationalSolange nicht anders angezeigt, wird die Lizenz wie folgt beschrieben: Attribution-NonCommercial-NoDerivatives 4.0 International

    Universidad de Valladolid

    Powered by MIT's. DSpace software, Version 5.10